

# Nicola Squillace

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6036495/publications.pdf>

Version: 2024-02-01

78  
papers

1,562  
citations

361296

20  
h-index

345118

36  
g-index

82  
all docs

82  
docs citations

82  
times ranked

2741  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade. <i>HIV Medicine</i> , 2022, 23, 70-79.	1.0	11
2	miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3486.	1.8	1
3	Reversibility of Central Nervous System Adverse Events in Course of Art. <i>Viruses</i> , 2022, 14, 1028.	1.5	8
4	Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 119-127.	0.9	15
5	The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1389-1392.	1.1	0
6	HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation. <i>HIV Medicine</i> , 2021, 22, 860-866.	1.0	3
7	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , 2021, 35, 342-353.	1.1	15
8	HIV and SARS-CoV-2 Co-Infection: What are the Risks?. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 3991-4014.	1.1	7
9	Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 19-26.	0.5	6
10	Cardiovascular Events Recurrence and Coronary Artery Disease in HIV Patients: The Price We Have to Pay for the Chronicization of the Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 127-134.	0.8	14
11	Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. <i>Aids</i> , 2020, 34, 53-61.	1.0	14
12	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405.	1.8	98
13	Factors associated with hospital admission for COVID-19 in HIV patients. <i>Aids</i> , 2020, 34, 1983-1985.	1.0	26
14	Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible From the STOPSHIV Project Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 496-503.	0.9	4
15	Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: Is There an Optimal Interleukin 6 Cutoff for Successful Tocilizumab Treatment?. <i>Clinical Infectious Diseases</i> , 2020, 73, e270-e271.	2.9	1
16	&lt;p&gt;Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2291-2300.	1.1	6
17	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (IN ACTION) cohort. <i>HIV Medicine</i> , 2020, 21, 523-535.	1.0	6
18	Factors Associated With Weight Gain in People Treated With Dolutegravir. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa195.	0.4	47

#	ARTICLE	IF	CITATIONS
19	Immunological failure in an HIV $\tilde{A}$ lite controller: possible role of indirect markers of inflammation and benefit of antiretroviral therapy. <i>Aids</i> , 2020, 34, 646-647.	1.0	0
20	Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. <i>Patient</i> , 2020, 13, 375-387.	1.1	5
21	Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study. <i>BMC Public Health</i> , 2020, 20, 734.	1.2	15
22	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection—Results of Italian Network of ACuTe HIV Infection (INACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	1.4	16
23	&lt;p&gt;The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5515-5520.	2.0	24
24	Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). <i>AIDS Research and Therapy</i> , 2019, 16, 21.	0.7	5
25	&lt;p&gt;Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1385-1391.	1.1	19
26	Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2019, 19, 555.	1.3	29
27	Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. <i>AIDS Research and Therapy</i> , 2019, 16, 11.	0.7	13
28	miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir. <i>Frontiers in Pharmacology</i> , 2019, 10, 461.	1.6	15
29	Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 643-650.	1.4	11
30	Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare.. <i>JHA - Journal of HIV and Ageing</i> , 2019, , .	0.0	0
31	SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients. <i>New Microbiologica</i> , 2019, 42, 150-155.	0.1	0
32	Higher Levels of Peripheral Th17 T CD4+ Cells Are Associated With Immunological Non Response in HIV-Infected Patients Under Effective ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, e45-e47.	0.9	2
33	Darunavir&ndash;cobicistat&ndash;emtricitabine&ndash;tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3635-3643.	2.0	12
34	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). <i>BMC Infectious Diseases</i> , 2018, 18, 357.	1.3	42
35	The NLRP3 Inflammasome Is Upregulated in HIV-Infected Antiretroviral Therapy-Treated Individuals with Defective Immune Recovery. <i>Frontiers in Immunology</i> , 2018, 9, 214.	2.2	71
36	Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 615-623.	1.1	17

#	ARTICLE	IF	CITATIONS
37	Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2162-2170.	1.3	6
38	La steatosi epatica non alcolica in HIV: una revisione critica della letteratura.. <i>JHA - Journal of HIV and Ageing</i> , 2018, , .	0.0	0
39	Clusterizzazione di comorbidità e multimorbidità tra le persone che vivono con HIV, e rischio di interazione malattia-malattia: report preliminare. <i>JHA - Journal of HIV and Ageing</i> , 2018, , .	0.0	0
40	Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, e76-e79.	0.7	7
41	Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. <i>Aids</i> , 2017, 31, 455-457.	1.0	47
42	Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated With the Evolution of Cognitive Performance in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 219-224.	0.9	16
43	Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. <i>PLoS ONE</i> , 2017, 12, e0179254.	1.1	17
44	Weight Gain: A Possible Side Effect of All Antiretrovirals. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx239.	0.4	68
45	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. <i>BMC Infectious Diseases</i> , 2017, 17, 551.	1.3	112
46	Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. <i>New Microbiologica</i> , 2017, 40, 139-142.	0.1	4
47	High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects. <i>Medicine (United States)</i> , 2016, 95, e4434.	0.4	2
48	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2663-2669.	1.3	10
49	Similar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, e37-e40.	0.9	3
50	Prospective Immune Dynamics during the First 24 Weeks of Efavirenz Based-Antiretroviral Therapy in HIV-1-Infected Subjects, According to CD4+ T-Cell Counts at Presentation: The IMMUNEF Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0117118.	1.1	6
51	Brachial and central blood pressure in HIV-infected subjects. <i>Hypertension Research</i> , 2015, 38, 405-412.	1.5	13
52	Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19573.	1.2	5
53	A Case of Cerebrospinal Fluid Viral Escape on a Dual Antiretroviral Regimen: Worth the Risk?. <i>Clinical Infectious Diseases</i> , 2014, 59, 1655-1656.	2.9	16
54	Focal bone lesions in hiv-positive patient treated with tenofovir. <i>BMC Infectious Diseases</i> , 2014, 14, 131.	1.3	4

#	ARTICLE	IF	CITATIONS
55	Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3067-3075.	1.3	26
56	Unmasking tuberculosis in the era of antiretroviral treatment. <i>European Respiratory Journal</i> , 2012, 39, 1064-1075.	3.1	12
57	Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: relapse or late IRIS?. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1190-1191.	1.3	1
58	Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 278.	0.9	6
59	Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: A pilot study. <i>Blood Pressure</i> , 2010, 19, 344-350.	0.7	3
60	Heterologous Fat Transplantation for the Treatment of HIV-Related Facial Lipoatrophy. <i>Annals of Internal Medicine</i> , 2009, 150, 61.	2.0	3
61	Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 927-933.	1.5	7
62	Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease. <i>HIV Medicine</i> , 2009, 10, 28-34.	1.0	12
63	The Role of the Framingham Risk Score to Predict the Presence of Subclinical Coronary Atherosclerosis in Patients with HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 303-304.	0.9	7
64	Detectable HIV Viral Load Is Associated With Metabolic Syndrome. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 459-464.	0.9	27
65	Body image is a major determinant of sexual dysfunction in stable HIV-infected women. <i>Antiviral Therapy</i> , 2009, 14, 85-92.	0.6	35
66	Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study. <i>HIV Medicine</i> , 2008, 9, 151-159.	1.0	3
67	Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 374-379.	1.3	15
68	Reply to Remtulla and Decker. <i>Clinical Infectious Diseases</i> , 2008, 47, 1234-1234.	2.9	0
69	Nonalcoholic Fatty Liver Disease in HIV-infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors. <i>Clinical Infectious Diseases</i> , 2008, 47, 250-257.	2.9	208
70	Severity of Lipodystrophy Is Associated with Decreased Health-Related Quality of Life. <i>AIDS Patient Care and STDs</i> , 2008, 22, 577-585.	1.1	41
71	Lipodystrophy and quality of life of HIV-infected persons. <i>AIDS Reviews</i> , 2008, 10, 152-61.	0.5	31
72	Long-Term Psychometric Outcomes of Facial Lipoatrophy Therapy: Forty-Eight-Week Observational, Nonrandomized Study. <i>AIDS Patient Care and STDs</i> , 2007, 21, 833-842.	1.1	25

#	ARTICLE	IF	CITATIONS
73	Prevalence of and Risk Factors for Pubic Lipoma Development in HIV-Infected Persons. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 45, 72-76.	0.9	14
74	Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. <i>Antiviral Therapy</i> , 2007, 12, 1059-65.	0.6	15
75	Sexual Dysfunction in HIV-Infected Men: Role of Antiretroviral Therapy, Hypogonadism and Lipodystrophy. <i>Antiviral Therapy</i> , 2007, 12, 1059-1066.	0.6	54
76	Multidisciplinary Approach to the Treatment of Metabolic and Morphologic Alterations of HIV-Related Lipodystrophy. <i>HIV Clinical Trials</i> , 2006, 7, 97-106.	2.0	45
77	Invasive pulmonary and cerebral aspergillosis in a patient with Weil's disease. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 396-398.	1.5	5
78	Tularaemia outbreak in Bulgaria. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 785-789.	1.5	36